China Implements New Measures for Priority Examination of Patents

CNIPA Order No. 85 takes effect on September 1, 2026, repealing the 2017 framework. The fast lane is no longer merely fast, it now demands proven innovation value and commercialisation prospects, and it can be lost mid-stream.

China’s patent fast lane has been rebuilt. On July 28, 2026, CNIPA Commissioner Shen Changyu signed Order No. 85 promulgating a revised “Measures for the Administration of Priority Examination of Patents”; the full text was published on 30 July and enters into force on September 1, 2026, repealing the 2017 Measures (Order No. 76) the same day. Where the 2017 framework ran to 15 articles, the new instrument has 24 articles across six chapters, and the additions are almost entirely about who gets in, on what evidence, and what happens when they misbehave.

The direction of travel is unambiguous. During the 14th Five-Year Plan period, Chinese authorities handled more than 720,000 priority examination requests. A channel originally designed to shorten pendency for strategically important filings is now being recast as a scarce, quality-gated resource aimed at “new quality productive forces”, known as emerging industries, future industries and key core-technology breakthroughs.

1. A Double Threshold Replaces the Sector Checklist

The most consequential change sits in Article 5. Previously, fitting into a listed industrial category was largely enough. Now, patent applications and re-examination cases must first clear a substantive gate. They must possess “important innovation value and commercialisation prospects”, and then also fall within one of five qualifying scenarios:

• emerging or future industries, or key core-technology research programmes;
• industries specifically encouraged by a provincial or prefecture-level municipal government;
• the patent applicant or re-examination requester has already commercialised the invention, is prepared to commercialise it, or holds evidence that a third party is working it;
• the application first filed in China for which substantive examination has since been requested abroad on the same subject matter;
• other circumstances of major significance to national or public interest.

Note the trade-off. The old fixed list of designated industry sectors has been dropped in favour of the open-ended “emerging and future industries,” giving the system room to move as technology shifts. But that flexibility transfers judgment to provincial IP offices and CNIPA examiners, and makes the evidentiary file, not the label, decisive.

2. Invalidation Cases Get a Much Wider Door

Article 6 substantially expands priority treatment for invalidation proceedings. Beyond infringement disputes already pending before a local IP office or a court, the triggers now expressly include: CNIPA administrative adjudication or mediation of major patent infringement disputes; administrative adjudication under the pharmaceutical patent early-resolution mechanism; mediation of open-licence disputes; and arbitration of patent licence contract disputes. Local IP offices, courts and arbitration institutions may themselves file the request.

For life sciences, semiconductors and any business whose launch timeline is exposed to a validity challenge, this is the most commercially significant item in the package: resolving a validity dispute in five months for inventions and utility models and four months for designs can materially de-risk a product launch or a licensing negotiation.

3. An Express Negative List

Article 8 codifies exclusions that were previously a matter of practice. Priority examination will generally be refused where: the case is a divisional whose parent already received accelerated examination; the applicant filed a utility model for the same invention-creation on the same day as the invention; the case has already granted priority or other accelerated treatment in the same proceeding; or Article 5(4) is invoked and the evidence shows the application obviously lacks patentability. The intent is to stop the same filing from consuming scarce examination capacity twice.

4. A Faster Clock and a Shorter Leash

All targets are subject to an express exception for complex or difficult cases (Article 15). As exchange, the applicant’s own deadlines tighten sharply: one month from the issue date of an office action for inventions, and fifteen days for utility models and designs (Article 16).

Priority is also revocable. Under Articles 17-18, CNIPA may terminate priority treatment and return the case to the ordinary queue where the applicant amends the application after approval, misses or seeks to extend a response deadline, supplements evidence or grounds (invalidation), amends claims other than by deletion (invalidation), or where the proceeding is suspended or depends on another case’s outcome (Re-examination and invalidation). False materials or other bad-faith conduct trigger the same consequence, plus a one-year bar on filing any new priority request, applicable to applicants and to patent agencies alike (Article 22).

Filing mechanics — what changes on September 1, 2026

• No additional official fee. Only statutory Patent Law fees apply (Art. 12).
• Electronic filing is mandatory (Art. 10). Prior-art / prior-design submissions are now optional rather than required (Art. 11).
• Recommendation required from a State Council department or the provincial IP office except for Art. 5(4) overseas-examination cases (Art. 11).
• All co-applicants must consent to the request (Art. 9).
• New request form (2026.08 version). The old form is discontinued. Requests filed before 1 September 2026 continue under the old Measures.
• New filing channel: re-examination and invalidation priority requests move to the “Patent Affairs Service” module of the Patent Business Handling System; the former “Re-examination & Invalidation” module no longer accepts them.

5. Quotas and the Centre-Local Bargain

Article 19 makes allocation explicitly dynamic: CNIPA will distribute and adjust each locality’s quota according to how well that locality administers the process, the quality of its recommendations and of subsequent prosecution, its IP protection and utilisation performance, and its support for key national industries and strategies, etc. Provinces, in turn, must publish their own recommendation rules and standards (Article 20). In practice, local recommendation practice, but not the national text alone, will determine access, and quota position will increasingly track a locality’s track record rather than its filing volume.

6. Practical Priorities

• Audit the 1 September 2026 line. Requests filed before that date continue under the 2017 rules; those filed on or after it fall under Order No. 85. Retire internal templates built on the old request form.
• Build a “reason-fact-evidence” record per case. Two layers are now needed: proof of innovation value and commercialisation pathway, plus proof of the specific qualifying scenario. A business licence, a sales contract and product photographs may evidence implementation, but they do not establish “important innovation value.”
• Check local criteria now. Recommendation standards, attachment lists, quotas and processing practice vary by province; where local rules have not yet been updated, do not rely on past experience.
• Assign response owners in advance. The response periods, one month from the issue date of an office action for inventions and fifteen days for utility models and designs, are much shorter than those for ordinary cases and can easily be missed, and a missed deadline forfeits priority status.

The bottom line. The fast lane has not been closed. It has been repriced, in evidence, in procedural discipline and in alignment with national industrial strategy. Applicants who treat priority examination as a filing-formality shortcut will find themselves back in the ordinary queue. Those who prepare a documented innovation-and-commercialisation case, and who can answer within the required response period, should find a more predictable and genuinely faster route to grant.